3 Reasons Why Growth Investors Shouldn't Overlook McKesson (MCK)

McKesson (MCK) is identified as a strong growth prospect by Zacks, holding a Growth Score of A and a Zacks Rank #2 (Buy). The prescription drug distributor exhibits robust fundamentals, including projected EPS growth of 12.7% this year, significantly exceeding the 6.9% industry average, and a high asset utilization ratio of 4.95 compared to the industry's 0.72. Additionally, sales are forecast to grow 13.1% and current-year earnings estimates have seen positive upward revisions, collectively positioning MCK as a potential outperformer for growth-oriented portfolios.

Analysis

McKesson (MCK) presents a compelling case for growth-oriented investors, underscored by its Zacks Rank #2 (Buy) and a Growth Score of 'A'. The company's fundamental strength is evident in its forward-looking financial projections, which significantly outpace industry benchmarks. Specifically, McKesson is projected to deliver EPS growth of 12.7% this year, nearly double the industry average of 6.9%. This earnings momentum is supported by robust top-line expectations, with sales forecast to increase by 13.1% versus the industry's 4.5%. A key differentiating factor is the company's exceptional operational efficiency, demonstrated by a sales-to-total-assets (S/TA) ratio of 4.95. This figure indicates that McKesson generates almost seven times more revenue per dollar of assets than the industry average of 0.72. Further bolstering the bullish thesis is the recent upward trend in earnings estimates, with the Zacks Consensus Estimate for the current year rising 0.1% in the past month, a factor historically correlated with positive near-term stock price movements.

Key Decisions for Investors

• Given the combination of a Zacks #2 (Buy) rank, an 'A' Growth Score, and superior financial metrics, investors with a growth mandate should consider McKesson a strong candidate for outperformance in the healthcare sector.
• It is critical to monitor the company's ability to maintain its exceptionally high asset utilization ratio (4.95) and achieve its projected double-digit earnings and sales growth, as these are the primary drivers of the current investment thesis.
• Investors should pay close attention to the trend in earnings estimate revisions, as the report suggests a strong correlation with near-term share price performance, making it a key forward-looking indicator to track.